Suppr超能文献

既往剖宫产术后阴道分娩指南。

Guidelines for vaginal birth after previous Caesarean birth.

作者信息

Martel Marie-Jocelyne, MacKinnon Catherine Jane

出版信息

J Obstet Gynaecol Can. 2004 Jul;26(7):660-83; quiz 684-6.

Abstract

OBJECTIVE

To provide evidence-based guidelines for the provision of a trial of labour (TOL) after Caesarean section.

OUTCOME

Fetal and maternal morbidity and mortality associated with vaginal birth after Caesarean (VBAC) and repeat Caesarean section.

EVIDENCE

MEDLINE database was searched for articles published from January 1995 to February 2004, using the key words "vaginal birth after Caesarean (Cesarean) section." The quality of evidence is described using the Evaluation of Evidence criteria outlined in the Report of the Canadian Task Force on the Periodic Health Exam.

RECOMMENDATIONS

  1. Provided there are no contraindications, a woman with 1 previous transverse low-segment Caesarean section should be offered a trial of labour after Caesarean with appropriate discussion of maternal and perinatal risks and benefits. The process of informed consent with appropriate documentation should be an important part of the birth plan in a woman with a previous Caesarean section. (II-2B) 2. The intention of a woman undergoing a TOL after Caesarean should be clearly stated and documentation of the previous uterine scar should be clearly marked on the prenatal record. (II-2B) 3. For a safe labour after Caesarean section, the woman should deliver in a hospital where an immediate Caesarean section is available. The woman and her health-care provider must be aware of the hospital resources and the availability of obstetric, anaesthesia, pediatric, and operating-room staff. (II-2A) 4. Each hospital should have a written policy in place regarding the notification and/or consultation for the physicians responsible for a possible immediate Caesarean. (III B) 5. Continuous electronic fetal monitoring of women attempting a TOL after Caesarean is recommended. (II-2A) 6. Suspected uterine rupture requires urgent attention and expedited laparotomy in order to attempt to decrease maternal and perinatal morbidity and mortality. (II-2A) 7. Oxytocin augmentation is not contraindicated in women undergoing a TOL after Caesarean. (II-2A) 8. Medical induction of labour with oxytocin may be associated with an increased risk of uterine rupture and should be used carefully after appropriate counselling. (II-2B)9. Medical induction of labour with prostaglandin E2 (dinoprostone) is associated with an increased risk of uterine rupture and should not be used except in rare circumstances after appropriate counselling. (II-2B) 10. Prostaglandin E1 (misoprostol) is associated with a high risk of uterine rupture and should not be used as part of a TOL after Caesarean. (II-2A) 11. A foley catheter may be used safely to ripen the cervix in a woman planning a TOL after Caesarean. (II-2A) 12. The available data suggest that a trial of labour in women with more than one previous Caesarean section is likely to be successful but is associated with a higher risk of uterine rupture. (II-2B) 13. Multiple gestation is not a contraindication to a TOL after Caesarean. (II-2B) 14. Diabetes mellitus is not a contraindication to TOL after Caesarean. (II-2B) 15. Suspected fetal macrosomia is not a contraindication to a TOL after Caesarean. (II-2B) 16. Women delivering within 18 to 24 months of a Caesarean section should be counselled about an increased risk of uterine rupture in labour. (II-2B) 17. Postdatism is not a contraindication to a TOL after Caesarean. (II-2B) 18. Every effort should be made to obtain the previous Caesarean section operative report to determine the type of uterine incision used. In situations where the scar is unknown, information concerning the circumstances of the previous delivery is helpful in determining the likelihood of a low transverse incision. If the likelihood of a lower transverse incision is high, TOL after Caesarean can be offered. (II-2B) VALIDATION: These guidelines were approved by the Clinical Practice Obstetrics and Executive Committees of the Society of Obstetricians and Gynaecologists of Canada.
摘要

目的

为剖宫产术后试产提供循证指南。

结果

剖宫产术后经阴道分娩(VBAC)及再次剖宫产相关的母婴发病率和死亡率。

证据

检索MEDLINE数据库1995年1月至2004年2月发表的文章,关键词为“剖宫产术后经阴道分娩”。证据质量依据加拿大定期健康检查特别工作组报告中概述的证据评估标准进行描述。

建议

  1. 若不存在禁忌证,既往有1次子宫下段横切口剖宫产史的女性,应在充分讨论母婴风险和益处后,给予剖宫产术后试产的机会。对于有剖宫产史的女性,知情同意过程及适当的文件记录应成为分娩计划的重要组成部分。(II-2B)2. 剖宫产术后试产女性的意愿应明确表述,产前记录中应清晰标注既往子宫瘢痕情况。(II-2B)3. 为确保剖宫产术后安全分娩,女性应在具备即刻剖宫产条件的医院分娩。女性及其医护人员必须了解医院资源以及产科、麻醉科、儿科和手术室工作人员的可利用情况。(II-2A)4. 每家医院应制定书面政策,规定负责可能即刻剖宫产的医生的通知和/或会诊事宜。(III B)5. 建议对剖宫产术后试产的女性进行连续电子胎儿监护。(II-2A)6. 怀疑子宫破裂需紧急处理并尽快行剖腹探查术,以降低母婴发病率和死亡率。(II-2A)7. 剖宫产术后试产的女性使用缩宫素加强宫缩并无禁忌。(II-2A)8. 使用缩宫素引产可能增加子宫破裂风险,经适当咨询后应谨慎使用。(II-2B)9. 使用前列腺素E2(地诺前列酮)引产与子宫破裂风险增加相关,除非在罕见情况下并经适当咨询,否则不应使用。(II-2B)10. 前列腺素E1(米索前列醇)与子宫破裂高风险相关,不应作为剖宫产术后试产的一部分使用。(II-2A)11. 对于计划剖宫产术后试产的女性,可安全使用Foley导尿管促宫颈成熟。(II-2A)12. 现有数据表明,既往有多次剖宫产史的女性试产可能成功,但子宫破裂风险较高。(II-2B)13. 多胎妊娠并非剖宫产术后试产的禁忌证。(II-2B)14. 糖尿病并非剖宫产术后试产的禁忌证。(II-2B)15. 怀疑胎儿巨大并非剖宫产术后试产的禁忌证。(II-2B)16. 应告知剖宫产术后18至24个月内分娩的女性分娩时子宫破裂风险增加。(II-2B)17. 过期妊娠并非剖宫产术后试产的禁忌证。(II-2B)18. 应尽一切努力获取既往剖宫产手术报告,以确定所采用的子宫切口类型。若瘢痕情况不明,既往分娩情况的信息有助于判断子宫下段横切口的可能性。若子宫下段横切口可能性较大,可给予剖宫产术后试产的机会。(II-2B)验证:这些指南经加拿大妇产科学会临床实践产科委员会和执行委员会批准。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验